Relmada Therapeutics (RLMD) News Today → The Sneaky IRS Tax Law that's Sweeping the U.S. (From Birch Gold) (Ad) Free RLMD Stock Alerts $3.85 0.00 (0.00%) (As of 12:13 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineRelmada Therapeutics (RLMD) Set to Announce Quarterly Earnings on Wednesdaymarketbeat.com - May 7 at 12:28 PMRelmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024prnewswire.com - May 6 at 7:30 AMRelmada Therapeutics (NASDAQ:RLMD) Shares Down 3.3% marketbeat.com - April 23 at 2:13 AMRELMADA THERAPEUT.DL-,001 (4E2.F)finance.yahoo.com - April 16 at 7:48 AMRelmada Therapeutics: Run Up Into Results May Resume Following This Dropseekingalpha.com - March 21 at 9:39 PMOptimistic Buy Rating for Relmada Therapeutics Amidst Strong Phase 3 Trial Prospects and Financial Stabilitymarkets.businessinsider.com - March 21 at 9:38 AMRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 20 at 3:29 PMRelmada Therapeutics, Inc.: Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Resultsfinanznachrichten.de - March 20 at 8:50 AMQ4 2023 Relmada Therapeutics Inc Earnings Callfinance.yahoo.com - March 20 at 8:50 AMRLMD Stock Earnings: Relmada Therapeutics Misses EPS for Q4 2023investorplace.com - March 19 at 10:01 PMRecap: Relmada Therapeutics Q4 Earningsbenzinga.com - March 19 at 5:41 PMRelmada Therapeutics Inc Reports Full-Year and Q4 2023 Financial Resultsfinance.yahoo.com - March 19 at 5:41 PMRelmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Resultsprnewswire.com - March 19 at 4:15 PMOptions Volatility and Implied Earnings Moves Today, March 19, 2024msn.com - March 19 at 12:40 PMRelmada Therapeutics FY 2023 Earnings Previewmsn.com - March 18 at 7:48 PMRLMD Apr 2024 2.500 putfinance.yahoo.com - March 16 at 7:13 PMRelmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conferenceprnewswire.com - March 5 at 7:30 AMSilverarc Capital Management LLC Acquires Shares of 100,000 Relmada Therapeutics, Inc. (NASDAQ:RLMD)marketbeat.com - February 18 at 12:54 PMRelmada Therapeutics Inc (RLMD)investing.com - February 13 at 5:44 PMAnalysts Are Bullish on Top Healthcare Stocks: Immunocore Holdings (IMCR), Thermo Fisher (TMO)markets.businessinsider.com - February 5 at 2:22 PMRelmada Therapeutics Inc.thestreet.com - February 4 at 7:57 AMRelmada Therapeutics And 2 Other Penny Stocks Insiders Are Buyingmsn.com - February 2 at 8:12 AMRelmada Therapeutics Shares Hit 52-Week High After Execs Buy Sharesmarketwatch.com - February 1 at 7:49 PMRelmada Therapeutics Inc CEO Sergio Traversa Acquires 100,000 Sharesfinance.yahoo.com - February 1 at 3:42 PMFY2024 Earnings Forecast for Relmada Therapeutics, Inc. Issued By Leerink Partnrs (NASDAQ:RLMD)marketbeat.com - January 31 at 7:19 AMRelmada Therapeutics Stock (NASDAQ:RLMD) Dividends: History, Yield and Datesbenzinga.com - January 30 at 4:34 PMLeerink Partnrs Weighs in on Relmada Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:RLMD)marketbeat.com - January 30 at 7:16 AMRelmada Therapeutics Inc RLMDmorningstar.com - January 23 at 9:16 PMRelmada Therapeutics, Inc.'s (NASDAQ:RLMD) market cap touched US$109m last week, benefiting both individual investors who own 39% as well as institutionsfinance.yahoo.com - January 23 at 9:10 AMMizuho sees weakness in Relmada Therapeutics shares as buying opportunityrealmoney.thestreet.com - January 4 at 11:48 PMRelmada Therapeutics Shares Slide as Medical Chief Exitsmarketwatch.com - January 4 at 1:48 PMRelmada Therapeutics, Inc.: Relmada Therapeutics Provides Corporate Updatefinanznachrichten.de - January 4 at 9:49 AMRelmada Therapeutics, Inc. (NASDAQ:RLMD) Short Interest Down 26.2% in Decembermarketbeat.com - December 30 at 10:39 AMBuy Rating for Relmada Therapeutics: Efficient Management, Promising Trials and Prudent Financial Controlmarkets.businessinsider.com - November 10 at 5:17 PMRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 10 at 5:17 PMRelmada Therapeutics GAAP EPS of -$0.73msn.com - November 8 at 5:45 PMRelmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 8 at 5:45 PMEarnings Outlook For Relmada Therapeuticsbenzinga.com - November 7 at 9:38 PMPositive Signs As Multiple Insiders Buy Relmada Therapeutics Stockfinance.yahoo.com - November 6 at 10:01 AMRelmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023finance.yahoo.com - November 3 at 8:16 AMRelmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023finance.yahoo.com - October 11 at 10:35 AMRelmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summitfinance.yahoo.com - October 9 at 8:21 AMRelmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congressfinance.yahoo.com - October 6 at 7:39 AMHere's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situationfinance.yahoo.com - September 26 at 7:13 AMRelmada (RLMD) Up on Positive Data for Anti-Depressant Candidatefinance.yahoo.com - September 21 at 5:37 PMRelmada Therapeutics' Lead Candidate Shows Promise In Pivotal Depression Studybenzinga.com - September 20 at 1:52 PMRelmada Therapeutics Shares Rise 18% After Positive Trial Data for REL-1017marketwatch.com - September 20 at 10:35 AMRelmada Therapeutics: Long-term Study With REL-1017 Shows Rapid, Sustained Therapeutic Effectsmarkets.businessinsider.com - September 20 at 8:51 AMRelmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorderfinance.yahoo.com - September 20 at 8:51 AMRelmada Therapeutics: Run Up Likely Into Phase 3 Results, Enhanced By Possible Interim Readoutmsn.com - September 1 at 9:03 PM Get Relmada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump is sounding the alarm (Ad)Europe is one of the latest to release a central bank digital currency and along with it, new cash rules. Christine Lagarde, President of the European Central Bank, shared "Now we have in Europe this threshold, above 1,000 euros you cannot pay cash… if you get caught you are fined or you are going to jail". Are you prepared? Click here to get your complimentary retirement guide! RLMD Media Mentions By Week RLMD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RLMD News Sentiment▼0.000.40▲Average Medical News Sentiment RLMD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RLMD Articles This Week▼11▲RLMD Articles Average Week Get Relmada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CytomX Therapeutics News Nuvectis Pharma News Rezolute News Abeona Therapeutics News Immunic News Repare Therapeutics News GlycoMimetics News Societal CDMO News Citius Pharmaceuticals News Cartesian Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RLMD) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyDave Ramsey Shocks Millions With US Dollar LunacyAmerican Hartford Gold GroupTrump is sounding the alarmPreserve GoldBiden’s Sneaky H.R. 5376 Is A Nightmare For Retirement SaversBirch GoldThe best inflation-proof investment DTIAI “wealth window” is closing June 25thParadigm PressThe 2024 crypto bull run has already started — don’t get left behindInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
